<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144443">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220297</url>
  </required_header>
  <id_info>
    <org_study_id>BMT209</org_study_id>
    <secondary_id>SU-09092009-3841</secondary_id>
    <nct_id>NCT01220297</nct_id>
  </id_info>
  <brief_title>Sirolimus &amp; Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT</brief_title>
  <official_title>Sirolimus and Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GVHD prophylaxis of sirolimus and mycophenolate mofetil for patients undergoing matched
      related allogeneic transplant for acute and chronic leukemia, MDS, high risk NHL and HL
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual
  </why_stopped>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of grade II-IV acute GVHD at D+100 post-transplant</measure>
    <time_frame>100 days post-transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grade III-IV acute GVHD</measure>
    <time_frame>100 days post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of MMF</measure>
    <time_frame>completion of study- at 2-3 years after institution</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Veno-occlusive Disease Incidence of Infection CMV reactivation</measure>
    <time_frame>100 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic GVHD Disease-free and Overall Survival</measure>
    <time_frame>approximately 1-2 years after completion of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil and platelet engraftment Thrombotic microangiopathy Severity of Mucositis</measure>
    <time_frame>100 days post-transplant per patient Thrombotic microangiopathy- as it occurs and/or 100 days post-transplant Mucositis- first 3 weeks post-transplant per patient; all patients - reviewed at completion of trial</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Hematologic Diseases</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>12 mg loading dose, 4 mg QD, PO</description>
    <other_name>rapamycin</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>15 mg/kg TID, IV or PO</description>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carmustine</intervention_name>
    <description>15 mg/kg, IV</description>
    <other_name>BCNU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VP-16</intervention_name>
    <description>60 mg/kg, IV</description>
    <other_name>Vmw65</other_name>
    <other_name>Î±-TIF</other_name>
    <other_name>Trans Inducing Factor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>100-120 mg/kg, IV</description>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Disease Categories (participants will have one of the following)

               -  AML, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease

               -  AML, age 51-60 years of age, in first or subsequent remission or
                  relapsed/refractory disease

               -  AML with multilineage dysplasia

               -  ALL, age 2 - 60 years beyond 2nd remission or relapsed/refractory disease

               -  ALL, age 51 - 60 years in first or subsequent remission or relapsed/refractory
                  disease

               -  CML Beyond 2nd chronic phase or in blast crisis

               -  MDS; Includes World Health Organization classifications of refractory anemia
                  with excess blasts-1 (RAEB-1), RAEB-2 and therapy-related MDS

               -  Myeloproliferative disorders; MDS with poor long-term survival including myeloid
                  metaplasia and myelofibrosis

               -  High risk NHL in first remission

               -  Relapsed or refractory NHL

               -  HL beyond first remission

          -  Males and females of any ethnic background 2 - 60 years of age

          -  Karnofsky Performance Status &gt;= 70% or Lansky performance status &gt; 70% for patients &lt;
             16 years of age.

          -  Matched related donor identified

               -  6/6 HLA-A, B and DRB1

          -  Willingness to take oral medications during the transplantation period

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Prior myeloablative allogeneic or autologous HCT

          -  HIV infection

          -  Pregnant or lactating females

          -  Evidence of uncontrolled active infection

          -  Organ Dysfunction

               -  Serum creatinine &gt; 1.5 mg/dL or 24 hour creatinine clearance &lt; 50 ml/min

               -  Direct bilirubin, ALT or AST &gt; 2 x ULN

               -  In adults DLCO &lt; 60% predicted and in children room air oxygen saturation &lt; 92%

               -  In adults, left ventricular ejection fraction &lt; 45% and in children, shortening
                  fraction &lt; 26%

          -  Fasting Cholesterol &gt; 300 mg/dL or Triglycerides &gt; 300 mg/dL while on lipid-lowering
             agents.

          -  Patients receiving investigational drugs unless cleared by the PI.

          -  Patients with prior malignancies except basal cell carcinoma or treated carcinoma
             in-situ. Cancer treated with curative intent &gt; 5 years will be allowed. Cancer
             treated with curative intent &lt;= 5 years will not be allowed with PI approval.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Johnston</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <lastchanged_date>October 7, 2011</lastchanged_date>
  <firstreceived_date>November 24, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Carmustine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
